Genomic Biomarkers for Pharmaceutical Development
-
Genomic Biomarkers for Pharmaceutical Development: Chapter 5. microRNA Biomarkers as Potential Diagnostic Markers for Cancer
By Elizabeth Mambo, Anna E. Szafranska-Schwarzbach, Gary LathamAhlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10 272–7, e1. Berger BM, Ahlquist DA.
-
Genomic Biomarkers for Pharmaceutical Development: Chapter 7. Translating Biomarker Discovery into Companion Diagnostics through Validation and Regulatory Consideration
By Philip Brohawn, Bahija Jallal, Brandon W. HiggsMethods to best maneuver this are presented to help emphasize the necessary level of validation for use of an assay in a clinical setting. Each pertinent stage is then described, and key focus areas are highlighted.
-
Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care
By Bahija Jallal, Koustubh Ranade, Yihong YaoThis book provides a complete picture of biomarker development and validation in a pharmaceutical setting while addressing the inherent challenges of targeting the appropriate indications, biomarker robustness, regulatory hurdles, ...
-
Genomic Biomarkers for Pharmaceutical Development: Chapter 6. Toxicogenomics – A Drug Development Perspective
By Yuping Wang, Weida Tong, Jürgen BorlakThis review introduces the concept of toxicogenomics, summarizes the prominent applications of this relatively young discipline in drug development, and provides a future perspective of advancement in this field.
-
Genomic Biomarkers for Pharmaceutical Development: Chapter 1. Application of Translational Science to Clinical Development
By Bahija Jallal, Brandon W. Higgs, Koustubh RanadeDespite the large and ever-growing investment in pharmaceutical R&D, the number of innovative new medicines that meet significant unmet medical needs has been stagnant, if not declining.
-
Genomic Biomarkers for Pharmaceutical Development: Chapter 2. Personalized Health Care (PHC) in Cancer
By Nicholas C. Dracopoli, Katie StreicherThe goal of personalized healthcare in the treatment of cancer is to reduce the attrition of novel oncology drugs and improve patient outcomes.
-
Genomic Biomarkers for Pharmaceutical Development: Chapter 3. Personalized Healthcare in Autoimmune Diseases
By Brandon W. Higgs, Yihong Yao, Cornelis L. VerweijAutoimmune diseases constitute a wide range of mostly complex and multifactorial disorders that are difficult to treat.
-
Genomic Biomarkers for Pharmaceutical Development: Chapter 4. Molecular Heterogeneity, Biomarker Discovery, and Targeted Therapy in Asthma
By Joseph R. Arron, Jeffrey M. HarrisAsthma is a heterogeneous disorder on molecular, cellular, physiological, and clinical levels, but there is a lack of consensus on how discrete subtypes of asthma should be defined.